Gamolenic acid - Scotia Pharmaceuticals

Drug Profile

Gamolenic acid - Scotia Pharmaceuticals

Alternative Names: Efamast; Efarmol; Epogam; Epogam Snip-Off capsules; Epostart; Gamma linolenic acid; Gamolenic acid/vitamin E; Primast; Primogam

Latest Information Update: 03 Oct 2011

Price : $50

At a glance

  • Originator Scotia Holdings [CEASED]; Scotia Pharmaceuticals [CEASED]
  • Class Small molecules; Unsaturated fatty acids
  • Mechanism of Action Cell adhesion molecule inhibitors; Immunomodulators; Prostaglandin synthase stimulants; Thromboxane synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Atopic dermatitis
  • Market Withdrawal Breast pain
  • Discontinued Breast cancer; Rheumatoid arthritis

Most Recent Events

  • 27 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 07 Oct 2002 The UK Medicines Control Agency has withdrawn the marketing authorisations for Evening primrose oil for atopic dermatitis (as Epogam) and mastalgia (as Efamast) in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top